The benefits of a VEGF-secreting endothelised scaffold on the survival of distal flaps with early pedicle flap division were evaluated in a rabbit model. We bioengineered a scaffold based on a fibrin matrix in which endothelial cells, genetically modified with a VEGF-encoding adenoviral vector were embedded. We distributed subjects in four groups.
Eight rabbits conditioned with endothelial cells embedded in a fibrin scaffold. The pedicle was divided after a period of 5 days; and eight rabbits conditioned with endothelial cells embedded in a fibrin scaffold but in this group the pedicle was divided after a period of 2 days.
Eight rabbits conditioned with VEGF-secreting endothelial cells embedded in a fibrin scaffold; the pedicle was divided after a period of 5 days. And eight rabbits conditioned with VEGF-secreting endothelial cells but the pedicle was divided after a period of 2 days. The percentages of survival were 95.62±4.95% for the VEGF-producing scaffold vs. 51.25±45.88% for a non-VEGF secreting scaffold when sectioning the pedicle after 5 days.
The percentage of survival of flaps in the group grafted with the VEGF-secreting scaffold was 55.62% compared to 2.5% in the group receiving the non-VEGF scaffold when the pedicle was sectioned after 2 days. The CD 31 immunostaining studies showed a dramatic increase in angiogenesis in the flaps conditioned by the VEGF-producing scaffolds. These data revealed that endothelised VEGF-secreting scaffold during flap creation could be a suitable approach in reconstructive surgery.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Plastic, Reconstructive & Aesthetic Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Pharmacological augmentation of skin flap viability: a hypothesis to mimic the surgical delay phenomenon or a wishful thought.Ann Plast Surg. 1989; 22: 293-306
- A comparative analysis of the ability of five classes of pharmacological agents to augment skin flap survival in various models and species: an attempt to standardize skin flap research.Ann Plast Surg. 1989; 23: 117-122
- Comparison of topical anti-ischemic agents in the salvage of failing random-pattern skin flaps in rats.Arch Facial Plast Surg. 1999; 1: 27-32
- Growth factors and flap survival.Microsurgery. 2004; 24: 162-167
- Accelerated flap prefabrication with vascular endothelial growth factor.J Reconst Microsurg. 2000; 16: 45-50
- Improved survival of ischemic random skin flaps through the use of bone marrow nonhematopoietic stem cells and angiogenic growth factors.Ann Plast Surg. 2005; 54: 546-552
- Vascular endothelial growth factor gene therapy in ischaemic rat skin flaps.Br J Plast Surg. 2002; 55: 55-58
- Gene therapy in flap survival.Microsurgery. 2004; 24: 168-173
- Nonviral transfer of genes to pig primary keratinocytes. Induction of angiogenesis by composite grafts overexpressing VEGF driven by a keratin promoter.Gene Ther. 1999; 6: 1734-1741
- Antiproliferative effects of PCA-4230, a new antithrombotic drug, in vascular smooth muscle cells.Br J Pharmacol. 1997; 120: 1360-1366
- Walker R.H. Technical manual. American Association of Blood Banks, Bethesda, MD1993: 728-730
- Transforming growth factor beta 1 improves wound healing and random flap survival in normal and irradiated rats.Arch Otolaryngol Head Neck Surg. 1996; 122: 171-177
- Improvement of TRAM flap viability using human VEGF induced angiogenesis: a comparative study of delay techniques.Plast Reconstr Surg. 2003; 112: 1032-1039
- Vascular endothelium growth factor, surgical delay, and skin flap survival.Ann Surg. 2004; 239: 866-873
- Utilizing angiogenic agents to expedite the neovascularization process in skin flaps.Laryngoscope. 1998; 98: 521-526
- Basic fibroblast growth factor has a beneficial effect on the viability of random skin flaps in rats.Ann Plast Surg. 1994; 32: 356-360
- Plastic surgical perspectives on vascular endothelial growing factor as gene therapy for angiogenesis.Plast Reconst Surg. 2000; 105: 1034-1041
- Vasodilator effect and mechanism of action of vascular endothelial growth factor in skin vasculature.Am J Physiol Heart Circ Physiol. 2004; 286: H946-H954
- Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor.J Cell Sci. 1995; 108: 2369-2379
- The effect of vascular endothelial growth factor on the healing of ischaemic skin wounds.Br J Plast Surg. 2003; 56: 334-341
- Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinoma.J Pathol. 2000; 192: 150-158
- Vascular endothelial growth factor-C, expression in human colorectal cancer tissues.Br J Cancer. 2000; 83: 887-891
- Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocytemacrophages in humans.Blood. 2001; 97: 785-791
- Effect of vascular endothelial growth factor on survival of random extension of axial pattern skin flaps in the rat.Ann Plast Surg. 1996; 37: 604-611
- Locally administered vascular endothelial growth factor cDNA increases survival of ischemic experimental skin flaps.Plast Reconst Surg. 1998; 102: 2033-2039
- Improvement of skin paddle survival by application of vascular endothelial growth factor in a rat TRAM flap model.Ann Plast Surg. 2001; 46: 314-319
- Improved perfusion after subcritical ischemia in muscle flaps treated with vascular endothelial growth factor.Plast Reconstr Surg. 2000; 106: 1541-1546
- Enhanced revascularization after angiogenic stimulation in a rabbit model of bilateral limb isquemia.Eur J Vasc Endovasc Surg. 1995; 9: 189-196
- The effects of VEGF on survival of a random flap in the rat: examination of various routes of administration.Br J Plast Surg. 2000; 53: 234-239
- Adenovirus mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia.Hum Gene Ther. 1998; 9: 1481-1486
- Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb.Lancet. 1996; 348: 370-374
- Vascular gene transfer.Curr Opin Lipidol. 1997; 8: 72-76
- Vectors for gene transfer to joints.Clin Orthop. 2000; 379S: S17-S30
- VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo.Cir Res. 1995; 77: 1077-1086
- Effect of cultured endothelial cells on angiogenesis in vivo.Plast Reconstr Surg. 1998; 101: 1552-1560
- Improved vitality of experimental random dorsal skin flaps in rats treated with enriched cell culture medium.Plast Reconstr Surg. 1999; 104: 148-151
- Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells.Circulation. 2004; 109: 1292-1298
- Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives.Circulation. 2004; 109: 656-663
Published online: January 22, 2007
Accepted: April 5, 2006
Received: January 13, 2006
© 2007 The British Association of Plastic Surgeons. Published by Elsevier Inc. All rights reserved.